Últimas noticias sobre Cardinal Health (NYSE:CAH) Bolsa

Cardinal Health

Cardinal Health is one of three leading pharmaceutical wholesalers in the us, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the us pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

CSCO

OUST

SERV

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este miércoles: EAT, SERV, CSCO, OUST y CAH.

5 acciones en el foco este miércoles: EAT, SERV, CSCO, OUST y CAH

Cardinal Health Inc

CARRIER ALLIANCE HLDGS by Carrier Alliance Holdings, Inc.

Carrier Alliance Holdings Inc

CELESTIAL ASIA SECS NEW by Celestial Asia Secs Holdings Ltd.

Celestial Asia Securities Holdings Ltd

Caro Holdings Inc

EVOLUTION MINING LTD ORD by Evolution Mining Ltd.

Evolution Mining Ltd

Morgan Stanley analyst Erin Wright maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Overweight and raises the price target from $127 to $136.

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $136

<a href="https://www.youtube.com/watch?v=fjFI9jPVh-A" title="https://www.youtube.com/watch?v=fjFI9jPVh-A">https://www.youtube.com/watch?v=fjFI9jPVh-A</a>

Biotech

Macro Economic Events

Global

Economics

General

President-Elect Donald J. Trump Says 'We're Going To Knock Out The Middlemen' Who Are Keeping Drug Prices High

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wolfe Research analyst Darrin Peller upgraded the rating for PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) from Peer Perform to Outperform and announced a $107 price target. PayPal shares closed at $89.40 on Thursday. See how other analysts view this stock.</li>
<li>B of A Securities analyst Tal Liani upgraded Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) from Neutral to Buy and raised the price target from $70 to $95. Ciena shares closed at $84.52 on Thursday. <a href="https://www.benzinga.com/quote/CIEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst Kyle Peterson upgraded Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) from Hold to Buy and announced a $100 price target. Upstart shares closed at $77.08 on Thursday. See how other analysts view this stock.</li>
<li>UBS analyst A.J. Rice upgraded the rating for Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Neutral to Buy and increased the price target from $79 to $80. Centene shares closed at $58.00 on Thursday. <a href="https://www.benzinga.com/quote/CNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Stephen Baxter upgraded the rating for Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from Underweight to Equal-Weight and raised the price target from $101 to $127. Cardinal Health shares closed at $117.46 on Thursday. <a href="https://www.benzinga.com/quote/CAH/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PYPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="622" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-1024x622.png" alt="" class="wp-image-691544" style="width:605px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-1024x622.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-768x466.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a></li>
</ul>

Upgrades

CIEN

PYPL

UPST

This PayPal Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Wells Fargo analyst Stephen Baxter upgrades Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from Underweight to Equal-Weight and raises the price target from $101 to $127.

Wells Fargo Upgrades Cardinal Health to Equal-Weight, Raises Price Target to $127

TTOO

T2 Biosystems To License Proprietary Technology For Direct-From-Whole-Blood Sepsis Pathogen Detection, Aiming To Generate Non-Dilutive Capital, Create Royalty Revenue Streams, And Broaden Adoption Of FDA-Cleared Diagnostics Powered By T2MR Detection And Adaptable Sample Processing Technology

FDA Says Cardinal Health Removes Some Monoject U-100 mL Insulin Syringe Luer Lock With Tip Cap Soft Packs

Cardinal Health Announced The U.S. Launch Of Its Kendall SCD SmartFlow Compression System, The Next Generation Of The Kendall Compression Series Offering An Enhanced Clinician And Patient Experience

Cardinal Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) short percent of float has fallen 26.42% since its last report. The company recently reported that it has 5.50 million shares sold short, which is 2.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.61 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cardinal Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732035620_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cardinal Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cardinal Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cardinal Health's peer group average for short interest as a percentage of float is 5.81%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Cardinal Health's Recent Short Interest

<ul>
<li>Acquisition of a majority stake in GI Alliance, the country's leading&nbsp;gastroenterology management services organization, to accelerate Cardinal Health's multi-specialty growth strategy</li>
<li>Acquisition of the Advanced Diabetes Supply Group, a leading national direct-to-patient provider of diabetes medical supplies, to accelerate Cardinal Health's at-Home Solutions growth strategy</li>
<li>Company announces plan to hold Investor Day in June 2025</li>
</ul>
Cardinal Health will acquire a majority stake in GI Alliance (GIA), the country's leading gastroenterology (GI) management services organization (MSO), from a combination of GIA physician owners and funds managed by affiliates of Apollo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>). Cardinal Health will purchase its majority stake for approximately $2.8 billion in cash, which will represent 71% ownership. GIA will operate as a platform within Cardinal Health's Pharmaceutical and Specialty Solutions segment. &nbsp;
Cardinal Health will also acquire the Advanced Diabetes Supply Group (ADSG), one of the country's leading diabetic medical supplies providers, for approximately $1.1 billion in cash. ADSG will merge with Cardinal Health's at-Home Solutions business.

Reported Earlier, Cardinal Health Accelerates Strategic Growth With $3.9B GI Alliance Acquisition And $1.1B Advanced Diabetes Supply Group Buyout

Morgan Stanley analyst Erin Wright maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Overweight and raises the price target from $119 to $127.

Morgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $127

Deutsche Bank analyst George Hill maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Hold and raises the price target from $119 to $124.

Deutsche Bank Maintains Hold on Cardinal Health, Raises Price Target to $124

UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $134 to $139.

UBS Maintains Buy on Cardinal Health, Raises Price Target to $139

Mizuho analyst Ann Hynes maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Neutral and raises the price target from $110 to $120.

Mizuho Maintains Neutral on Cardinal Health, Raises Price Target to $120

Barclays analyst Stephanie Davis maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Overweight and raises the price target from $117 to $133.

Barclays Maintains Overweight on Cardinal Health, Raises Price Target to $133

Wall Street rebounded Friday following Thursday&#8217;s selloff, yet midday gains were still insufficient to prevent a second consecutive weekly decline for the S&amp;P 500, currently <a href="https://www.benzinga.com/markets">down 1% for the week. </a>
Concerns over tech earnings eased after Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) outperformed expectations, restoring some risk appetite and supporting the sector rebound.
Amazon shares surged over 6%, heading for their best session since February.
The Nasdaq 100, up by 1.1%, outperformed the S&amp;P 500, up 0.8%. 
In economic data, the U.S. economy added just 12,000 jobs in October, a steep drop from the 223,000 gain in September and well below the forecast of 113,000, as hurricanes and strikes led to hiring freezes nationwide. 
Despite the weak job figures, the unemployment rate held steady at 4.1%, indicating companies chose to retain workers rather than downsize.
The ISM Manufacturing PMI signaled contraction for the seventh consecutive month in October, with the index missing estimates.
Oil prices experienced a volatile session, initially spiking on reports of an imminent retaliatory attack by Iran on Israel before pulling back as those concerns faded. Gold edged down 0.1%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) dipped 0.3%, slipping below the $70,000 mark.
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % change</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,123.15</td>
<td>1.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,161.88</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,751.05</td>
<td>0.8%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,209.70</td>
<td>0.6%</td>
</tr>
</tbody>
</table>
</figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.9% to $573.75.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 1.1% to $422.09.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rallied 1.2% to $489.80.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.8% to $219.26.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, rising 2%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 1.4%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), down 1.6%.</li>
<li>Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), up over 6%.</li>
<li>Atlassian Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>), up 20%.</li>
<li>Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), down 0.7%.</li>
<li>Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), up 2.8%.</li>
<li>Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>), up 13%.</li>
<li>Dominon Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>), down 0.2%.</li>
<li>Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), up 6%.</li>
<li>CBOE Global Markets Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#NYSE">CBOE</a>), down 2.9%.</li>
<li>Waters Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>), up 17%.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41690576/apple-q4-results-better-than-feared-analysts-highlight-iphone-16-demand-apple-intel">Apple Q4 Results &#8216;Better-Than-Feared&#8217;: Analysts Highlight iPhone 16 Demand, Apple Intelligence Opportunity After &#8216;Rock Solid Quarter&#8217;</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

Large Cap

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Tech

ETFs

$BTC

AAPL

AMZN

CBOE

CHTR

SPDR Dow Jones Industrial Average ETF Trust

INTC

TEAM

Select Sector SPDR-Consumer Discretionary

Tech Stocks Surge But S&P 500 Faces Second Weekly Decline, Amazon Rallies, Bitcoin Drops Below $70,000: What's Driving Markets Friday?

U.S. stocks were higher, with the Dow Jones index gaining around 450 points on Friday.
Shares of Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) rose sharply during Friday's session as the company posted stronger-than-expected results for the <a href="https://www.benzinga.com/quote/AMZN">third quarter on Thursday</a>.
Amazon reported third-quarter net sales of $158.9 billion, up 11% year-over-year. The total beat a Street consensus estimate of $157.2 billion, according to data from Benzinga Pro. The company said it sees fourth-quarter net sales to come in a range of $181.5 billion to $188.5 billion, up 7% to 11% year-over-year.
Amazon.com shares jumped 7.1% to $199.63 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Proto Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) shares jumped 31.8% to $36.10 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) gained 30% to $22.72 after the company reported better-than-expected third-quarter financial results and raised its FY24 net sales guidance above estimates.</li>
<li>Globalstar, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NYSE">GSAT</a>) jumped 25.3% to $1.3145 after the company amended its services agreement with Apple to launch an extended MSS network with new satellites and infrastructure.</li>
<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) gained 19.7% to $19.52.</li>
<li>Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) rose 17.3% to $378.98 after the company reported third-quarter earnings and sales that beat analyst estimates.</li>
<li>Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) gained 16.5% to $96.73 following third-quarter results.</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) climbed 15.8% to $218.37 after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates.</li>
<li>Pediatrix Medical Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) rose 15.6% to $14.26 following better-than-expected quarterly earnings.</li>
<li>ASP Isotopes Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) gained 14.2% to $7.98. ASP Isotopes announced the pricing of public offering of common stock.</li>
<li>Select Medical Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) surged 13.2% to $36.32 following better-than-expected quarterly earnings.</li>
<li>Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) gained 12% to $366.93 after the company reported better-than-expected quarterly EPS and revenues.</li>
<li>Liberty Broadband Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBRDA#NASDAQ">LBRDA</a>) gained 11.5% to $89.49.</li>
<li>Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) gained 9.9% to $55.56 after the company reported better-than-expected quarterly financial results and issued FY24 adjusted EPS guidance above estimates.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) rose 9.6% to $14.92.</li>
<li>MasTec, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) surged 8.2% to $133.01 after the company raised its FY2024 adjusted EPS guidance.</li>
<li>Chart Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NASDAQ">GTLS</a>) gained 8.1% to $130.46 following quarterly results.</li>
<li>Dorman Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DORM#NASDAQ">DORM</a>) gained 7.9% to $123.05 following upbeat earnings.</li>
<li>Magna International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGA#NYSE">MGA</a>) jumped 7.8% to $42.54 following third-quarter results.</li>
<li>Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) gained 7.1% to $116.21 after the company reported better-than-expected first-quarter EPS and revenues and raised its FY2025 adjusted EPS guidance.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41685620/top-3-energy-stocks-that-are-preparing-to-pump-in-november">Top 3 Energy Stocks That Are Preparing To Pump In November</a></li>
</ul>

Intraday Update

Movers

ADMA

ASPI

DORM

GSAT

GTLS

HALO

LBRDA

MBLY

PRLB

TILE

Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday

Cardinal Health Executive Says Company Will Actively Evaluate Additional Opportunities To Accelerate Growth In Specialty Therapeutic Areas; GLP-1 Drugs Are Continuing To Contribute To Revenue And "Grow More So Than We Had Originally Expected"

Friday,&nbsp;Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) reported first-quarter 2025 adjusted EPS of $1.88, up 9% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.62</a>.
Sales decreased 4% to $52.28 billion, beating the&nbsp;consensus of $50.90 billion. Adjusted operating earnings increased 12% to&nbsp;$625 million.
First-quarter revenue for the Pharmaceutical and Specialty Solutions segment decreased by 5% to&nbsp;$48.0 billion. Excluding the customer contract expiration, revenue increased by 16%, driven by brand and specialty pharmaceutical sales growth <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41679244/cardinal-health-reports-first-quarter-fiscal-year-2025-results-and-raises-fiscal-year-2025-outlook" rel="noreferrer noopener">from existing customers</a>.
Pharmaceutical and Specialty Solutions segment profit increased 16% to&nbsp;$530 million, driven by a higher contribution from brand and specialty products, including the earlier seasonal launch of COVID-19 vaccine distribution and positive generics program performance.
The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty drugs, and OTC products and offers services for specialty pharmaceuticals, supporting both manufacturers and healthcare providers and pharmacy management services.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40694838/opioid-settlement-drug-distributors-mckesson-cencora-cardinal-health-to-pay-300m-to-health-insurer" rel="noreferrer noopener">Opioid Settlement: Drug Distributors McKesson, Cencora, Cardinal Health To Pay $300M To Health Insurers</a>
Revenue for the Global Medical Products and Distribution segment increased 3% to&nbsp;$3.1 billion, driven by volume growth from existing customers.
Global Medical Products and Distribution (GMPD) segment profit decreased to&nbsp;$8 million, primarily due to higher manufacturing and health and welfare costs, largely offset by improved net inflationary impacts, including mitigation initiatives and growth from existing customers.
GMPD segment manufactures, sources, and distributes Cardinal Health brand medical, surgical, and laboratory products, as well as distributes medical, surgical and laboratory products known as national brand products
&#8220;We began fiscal 2025 by delivering strong operational and financial performance, led by the Pharmaceutical and Specialty Solutions segment,&#8221; said&nbsp;Jason Hollar, CEO of Cardinal Health.
&#8220;The strength and resiliency of our largest and most significant business continues to shine, giving us confidence to raise our fiscal 2025 enterprise guidance only a quarter into the year,&#8221; Hollar added.
Outlook:&nbsp;Cardinal Health has raised its fiscal year 2025 outlook for adjusted EPS to $7.75-$7.90 from <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40364087/pharma-distribution-giant-cardinal-health-lifts-2025-guidance-after-q4-earnings-beat-raises-stock-b" rel="noreferrer noopener">prior guidance of</a> $7.55-$7.70 versus consensus of $7.63.
The guidance includes an update to the company&#8217;s Pharmaceutical and Specialty Solutions segment profit outlook to 4% to 6% growth, from 1% to 3% growth.
The company also updated its Global Medical Products and Distribution segment profit outlook to&nbsp;$140 million&nbsp;to&nbsp;$175 million, from approximately&nbsp;$175 million, primarily due to the impact of higher health and welfare costs.
Additionally, the company updated expectations for its adjusted free cash flow to&nbsp;$1.0 billion&nbsp;to&nbsp;$1.5 billion, from approximately&nbsp;$1.0 billion.
Price Action: CAH stock is trading 2.97% higher at $111.74 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41661764/ford-to-halt-f-150-ev-production-for-7-weeks-next-month" target="_blank" rel="noreferrer noopener">Ford To Halt F-150 EV Production For 7 Weeks Next Month</a></li>
</ul>
Photo via Company

Guidance

Health Care

Cardinal Health Raises 2025 Profit Outlook Again, Helped By Strong Drug Distribution Business

Investors on Wall Street could see some respite after major indices registered a downbeat session on Thursday. Index futures point to a positive start on Friday, ahead of the crucial monthly report on jobs data.
Thursday was a busy day as far as tech earnings are concerned, with Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) reported their September quarter results.
While Meta and Microsoft both fell in after-market hours, Amazon surged after the company handily beat Street consensus. The company expects its fourth-quarter sales to surge between 7% to 11%.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.47%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.39%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.35%</td>
</tr>
<tr>
<td>R2K</td>
<td>0.12%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.43% to $571.07 and the Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) gained 0.51% to $486.33, according to<a href="https://benzinga.grsm.io/lxquj26b2sag"> Benzinga Pro data</a>.
Cues From Last Session:
All three major indices registered a downbeat Thursday, with S&amp;P 500 and Nasdaq Composite posting their biggest single-day fall since Sept. 3.
The overall investor sentiment declined, with the Greed index entering the "Fear" territory.
Most sectors on the S&amp;P 500 closed on a negative note, with information technology, consumer discretionary, and real estate stocks recording the biggest losses on Thursday. However, utilities and energy stocks bucked the overall market trend, closing the session higher.
Crude oil prices edged up, mostly recovering their losses over the previous weekend due to Israel's missile strikes on Iran.
Treasury yields continued to climb amid fears of higher deficits due to a possible re-election of former President Donald Trump.
Besides, the International Monetary Fund has also warned about the long-term trajectory <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41495286/deficit-strain-in-washington-will-get-worse-imf-warns-national-debt-projections-rev">of U.S. national debt</a>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-2.76%</td>
<td>18,095.15</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.86%</td>
<td>5,705.45</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.90%</td>
<td>41,763.46</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.63%</td>
<td>2,196.55</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Ryan Detrick, Chief Market Strategist at Carson Group, highlighted that November is the "best month of the year" as far as equity markets are concerned.
"The last time it fell more than 1% was in 2008, and it has been higher 11 of the past 12 years. Not to be outdone, it is the best month since 1950, in the past decade, and in election years, while it ranks as the second-best month the past 20 years (only July is better)."
Detrick <a href="https://www.carsongroup.com/insights/blog/seven-reasons-this-bull-market-is-alive-and-well/">added</a> that the bull market is here to stay. After experiencing a bull run for the past three years, the expert highlighted that "the potential for many more years of gains is actually quite high."
WisdomTree and Wharton School economist&nbsp;Jeremy Siegel, too, thinks earnings will beat interest rates, but there's something more important to consider.
He added that there could be increased anxiety in the markets until the election is over, after which there could be a bounce back.
However, Siegel added that he now anticipates only three 25-basis point rate cuts between now and June next year.
"Earnings will trump interest rates for stocks, but certainly for bonds, they are not good," Siegel told CNBC in <a href="https://www.cnbc.com/video/2024/10/31/earnings-will-trump-interest-rates-for-stocks-but-not-bonds-says-whartons-jeremy-seigel.html">an</a> interview.
On the economic data front, U.S. initial jobless claims declined by 12,000 from the previous week to 216,000 in the week ending Oct. 26.
The personal consumption expenditure price index rose 0.2% month-over-month in September following a 0.1% increase in August.
See Also: <a href="https://www.benzinga.com/money/best-futures-trading-software">Best Futures Trading Software</a>
Upcoming Economic Data:
<ul>
<li>The monthly jobs report is scheduled to be released at 8 a.m. ET.</li>
<li>S&amp;P&#8217;s final U.S. manufacturing PMI will be released at 9:30 a.m. ET.</li>
<li>Construction spending data will be released at 10 a.m. ET.</li>
<li>Auto sales data is expected to be released during the day.</li>
</ul>
Stocks In Focus:
<ul>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares fell 1.2% in premarket even as the company posted record quarterly revenue on the back of a rebound in iPhone sales.</li>
<li>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) will be on investors' radar after the company reported better-than-expected results during the September quarter. The stock is up 6.8% in premarket trading.</li>
<li>Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) is up nearly 6% in premarket trading even after the company posted a record loss of $16.6 billion during the September quarter.</li>
<li>Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) shares surged 1.3% in premarket trading after the company beat earnings per share (EPS) estimates, even though it posted a slight miss on revenue.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares continued to fall amid increased volatility, falling 3.3% in premarket trading. The stock fell 11.7% on Thursday.</li>
<li>Investors are awaiting earnings results from Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures gained in the early New York session, rising 2.08% as Iran prepares for another attack on Israel.
The benchmark 10-year Treasury note yield rose marginally to 4.289%.
Most Asian markets closed in the red on Friday, while European stocks were mostly higher in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41663633/biggest-gold-etf-posts-highest-monthly-inflows-in-2-5-years-as-investors-rush-to-">Biggest Gold ETF Posts Highest Monthly Inflows In 2.5 Years As Investors Rush To Safe Haven Ahead Of Presidential Election</a></li>
</ul>
Photo courtesy: Wikimedia

Futures

Federal Reserve

US Stocks Likely To Open Higher After 'Mag 7' Wrap Up Busy Week, Apple, Amazon And Intel On Radar: Investors Eye Monthly Jobs Report, Economist Says Earnings Won't Trump Bonds

WIIM

Cardinal Health shares are trading higher after the company reported better-than-expected Q1 EPS and revenues and raised its FY2025 adjusted EPS guidance.

Pioneer Balanced ESG Fund Q3 2024 Performance And Market Commentary

Pioneer Global Sustainable Equity Fund Q3 2024 Performance And Market Commentary

Wells Fargo upgraded Cardinal Health (CAH) to Equal Weight from Underweight with a price target of $127, up from $101. Published first on TheFly – ...

Cardinal Health upgraded to Equal Weight from Underweight at Wells Fargo

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Salesforce upgraded, ServiceNow downgraded: Wall Street's top analyst calls

Dividend aristocrats are known for their market resilience, and regular dividend increases, benefitting investors. Hence, investing in fundamentally sound dividend aristocrat stocks Emerson Electric (EMR), Cardinal Health (CAH), and Dover (DOV) could be wise for consistent payouts. Read more... Dividend aristocrats are well-established and well-performing companies that enjoy sharing their profits with their shareholders in the form of dividends. Their long history of dividend payments and consistent dividend increases appeal to a large number of investors who are seeking regular income and stability.
Against this backdrop, it could be wise to invest in dividend aristocrats stocks Emerson Electric Co. (<a href="https://stocknews.com/stock/EMR/">EMR</a>), Cardinal Health, Inc. (<a href="https://stocknews.com/stock/CAH/">CAH</a>), and Dover Corporation (<a href="https://stocknews.com/stock/DOV/">DOV</a>) for stability and long-term gains.
Owing to contributing factors like increased consumer spending, exports, federal government spending, and a rise in business investment, the <a href="https://www.bea.gov/news/glance">U.S. real GDP grew at 2.8%</a> during the third quarter of 2024. While the growth was optimistic, it lagged behind the second quarter's GDP growth of 3.0%, showing mixed signs.
During October alone, personal income increased by $147.4 billion or 0.6%, and disposable personal income increased by $144.1 billion or 0.7% over the same period.
Amid the economy's current trends, investors could lean towards stocks of companies that pay regular dividends to maintain stability and add a regular income stream. In the dividend stocks segment, <a href="https://www.investopedia.com/terms/d/dividend-aristocrat.asp">dividend aristocrats</a> are companies falling in the S&amp;P 500 index, which increases the size of their payouts annually.
Dividend aristocrats are large-sized, well-established entities with stable profits and high dividend yields and who have maintained dividend payments to shareholders for at least 25 straight years. They also offer safeguards against market turmoil and allow optimum diversification.
Therefore, dividend aristocrats are an ideal addition to enhance investment portfolio diversification, combat market uncertainties, and gain reliable income. Considering these encouraging trends, let's delve into the fundamentals of the top dividend aristocrats who have grown their dividends for more than 25 years.
Emerson Electric Co. (<a href="https://stocknews.com/stock/EMR/">EMR</a>)
EMR is a technology and software company that offers various solutions internationally. The company operates in seven segments: Final Control; Measurement &amp; Analytical; Discrete Automation; Safety &amp; Productivity; Control Systems &amp; Software; Test &amp; Measurement; and AspenTech.
On November 19, EMR made a strategic investment through its corporate venture capital arm, Emerson Ventures, in EECOMOBILITY, a startup that specializes in advanced battery testing and monitoring software. The company's strategic investment supports advanced AI software for rapid production testing of batteries.
On November 5, EMR declared a quarterly cash dividend increase to $0.5275 per share of common stock, which was paid on December 10, 2024, to stockholders of record on November 15, 2024.
EMR has raised its dividend for 28 consecutive years. It pays an annual dividend of $2.11, which translates to a yield of 1.61% at the current share price. Its four-year average dividend yield is 2.19%. Moreover, the company's dividend payouts have increased at a CAGR of 1.3% over the past five years.
Also, on the same date, the company announced three key strategic and financial actions for the final phase of its portfolio transformation into an industrial technology leader focused on automation. This included a proposal to acquire the remaining outstanding shares of AspenTech for $240 per share in cash, a review of strategic alternatives, and plans to repurchase shares.
EMR reported net sales of $4.62 billion for the fourth quarter that ended September 30, 2024, up 12.9% year-over-year. Its adjusted segment <a href="https://www.investopedia.com/terms/e/ebita.asp">EBITA</a> increased 15.8% from the prior year's quarter to $1.21 billion. The company's net earnings came in at $968 million, indicating growth of 31.2% year-over-year, and its adjusted EPS grew by 14.7% from the year-ago value to $1.48.
Furthermore, the company's free cash flow increased 10.1% from the previous year's period to $905 million.
Analysts expect EMR's revenue and EPS for the first quarter (ending December 2024) to grow 2.8% and 5.1% year-over-year to $4.23 billion and $1.28, respectively. Also, the company topped the consensus EPS estimates in all of the four trailing quarters, which is promising.
Shares of EMR have surged 20.9% over the past six months and 45% over the past year to close the last trading session at $131.16.
EMR's solid fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. It has an overall rating of B, translating to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
EMR has a B grade for Momentum and Quality. It is ranked #34 out of 89 stocks in the <a href="https://stocknews.com/category/industrial-equipment/">Industrial - Equipment</a> industry.
In addition to the POWR Ratings we've stated above, we also have EMR ratings for Growth, Value, Sentiment, and Stability. Get all EMR ratings <a href="https://stocknews.com/stock/EMR/">here</a>.
Cardinal Health, Inc. (<a href="https://stocknews.com/stock/CAH/">CAH</a>)
CAH operates internationally as a healthcare services and products company. The company provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It operates in Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution segments.
On November 20, CAH released its Kendall SCD SmartFlow&#x2122; compression system, the next generation of the Kendall&#x2122; compression series providing enhanced clinician and patient experience. The new system helps prevent venous thromboembolism events, enhance blood circulation, and treat pain and swelling related to venous stasis.
On November 11, CAH entered into definitive agreements to acquire two companies. CAH will purchase majority stakes of GI Alliance for approximately $2.8 billion in cash. It will also acquire the Advanced Diabetes Supply Group for around $1.1 billion in cash. The strategic acquisition of the two companies will accelerate CAH's strategic growth areas and enhance patient care.
On November 5, CAH's Board of Directors approved a quarterly dividend of $0.5056 per share. The dividend will be paid on January 15, 2025, to shareholders of record at the close of business on January 2, 2025.
CAH's annual dividend payment of $2.02 translates to a yield of 1.72% at the current share price. Its four-year average dividend yield is 2.78%. Also, the company's dividend payouts have increased at a CAGR of 1% over the past three years. CAH has raised its dividends for 29 consecutive years.
For the first quarter that ended September 30, 2024, CAH posted revenue of $52.28 billion, and its non-GAAP operating earnings grew 12.2% from the year-ago value to $625 million. Also, the company's non-GAAP net earnings attributable to CAH stood at $460 million or $1.88 per common share, reflecting growth of 7% and 9.3% from the prior-year quarter, respectively.
For the fiscal year 2025, the company raised its guidance for non-GAAP EPS attributable to CAH to $7.75 to $7.90 from the previous range of $7.55 to $7.70. It also updated its Pharmaceutical and Specialty Solutions segment profit outlook to 4% to 6% growth from the prior 1% to 3% range.
Street expects CAH's EPS for the third quarter (ending March 2025) to increase 5.2% year-over-year to $2.19. For the fiscal year (ending June 2025), the company's EPS is expected to grow 3.8% year-over-year to $7.82. Also, the company has topped the consensus EPS estimates in all four trailing quarters.
CAH's stock has gained 18.7% over the past six months and 8.8% over the past year to close the last trading session at $117.46.
CAH's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has a B grade for Value and Sentiment. CAH is ranked #12 among 62 stocks in the <a href="https://stocknews.com/category/medical-services/">Medical - Services</a> industry.
<a href="https://stocknews.com/stock/CAH/">Click here</a> to access CAH's Quality, Growth, Stability, and Momentum ratings.
Dover Corporation (<a href="https://stocknews.com/stock/DOV/">DOV</a>)
DOV offers equipment and components, consumable supplies, aftermarket parts, software and digital solutions, and support services globally. It operates in segments like: Engineered Products; Clean Energy &amp; Fueling; Imaging &amp; Identification; Pumps &amp; Process Solutions; and Climate &amp; Sustainability Technologies.
On December 11, DOV's wholly owned subsidiary Markem-Imaje launched its Ultraply ribbons and self-adhesive labels range. Amid the rapid rise of e-commerce and direct-to-consumer models, the new range addresses the growing demand for high-quality, phone-scannable 2D barcodes with its innovative Print and Apply (P&amp;A) labelers.
On November 7, DOV's Board of Directors declared a regular quarterly cash dividend of $0.515 per share, payable on December 16, 2024, to shareholders of record as of November 29, 2024.
DOV's annualized dividend of $2.06 per share translates to a dividend yield of 1.02% on the current share price. Its four-year average yield is 1.34%. Its dividend payouts have increased at 1.1% CAGR over the past five years. Also, DOV has raised its dividends for 68 consecutive years.
For the third quarter ended September 30, 2024, DOV's revenue increased marginally year-over-year to $1.98 billion. The company's gross profit grew 3.2% from the year-ago value to $763.19 million. Adjusted earnings from continuing operations amounted to $313.99 million and $2.27 per share, up 4.3% and 6.1% from the prior year's quarter, respectively.
For the fiscal year 2024, the company expects revenue growth of 1% to 3%. Its adjusted EPS from continuing operations is expected to be between $8.08 and $8.18.
Street expects DOV's revenue for the fiscal year (ending December 2025) to increase 5.1% year-over-year to $8.20 billion, and its EPS is expected to grow 14.9% year-over-year to $9.39 for the same period. Further, the company has surpassed the consensus EPS estimates in all of the trailing four quarters.
Over the past six months, DOV's stock has surged 10.8% and 38.4% over the past year to close the last trading session at $201.36.
DOV's sound fundamentals are reflected in its POWR Ratings. The stock has a B grade for Momentum, Quality, and Stability. Within the A-rated <a href="https://stocknews.com/category/industrial-machinery/">Industrial - Machinery</a> industry, DOV is ranked #43 out of 79 stocks.
<a href="https://stocknews.com/stock/DOV/">Click here</a> to access additional ratings of DOV for Sentiment, Value, and Growth.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
EMR shares were trading at $130.63 per share on Friday afternoon, down $0.53 (-0.40%). Year-to-date, EMR has gained 36.74%, versus a 28.36% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/emr-cah-dov-3-dividend-aristocrats-with-consistent-payouts/>3 Dividend Aristocrats With Consistent Payouts</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Dividend Aristocrats With Consistent Payouts

Morgan Stanley analyst Erin Wright maintained a Buy rating on Cardinal Health (CAH – Research Report) today and set a price target of $136.00. The ...

Morgan Stanley Keeps Their Buy Rating on Cardinal Health (CAH)

Miller-Howard Income-Equity Q3 2024 Commentary

Morgan Stanley raised the firm's price target on Cardinal Health (CAH) to $136 from $127 and keeps an Overweight rating on the shares. Diversified ...

Cardinal Health price target raised to $136 from $127 at Morgan Stanley

CII: 8.5% Income, 7% Discount, And Lower Volatility

AAVMY

ABBV

ABMRF

BABA

BABAF

BACRP

EDIT

EPDU

EXPE

FUJHF

FUJHY

GOOG

GOOGL

HAGHY

HNSDF

HOLX

LAMR

LRCX

MSFT

NVDA

PENN

PRYMF

PRYMY

PSMMF

PSMMY

PSTG

RLTY

SHEL

SPXX

SSNC

SSNLF

TASK

TRGP

TSLA

Press Releases

T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens

Cardinal Health celebrates medical product distribution center grand opening in Massachusetts

Cardinal Health Reports First Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook

Dividends

Cardinal Health Board of Directors Approves Quarterly Dividend

Cardinal Health announces two strategic additions to its portfolio

GI Alliance to Partner with Cardinal Health Creating a Scaled Multi-Specialty Managed-Services Platform to Benefit Physicians and Patients

Court Square Capital Partners Announces Sale of Advanced Diabetes Supply Group

Cardinal Health launches Kendall SCD SmartFlow™ Compression System

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

Cardinal Health to Announce Second-Quarter Results for Fiscal Year 2025 on January 30

Comments

Cardinal Health

Noticias

Últimas noticias sobre Cardinal Health (NYSE:CAH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL